Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making

The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.